Page 138 - 2019_10 resto del Mondo_web

R. Bassan et al.
subgroups that we examined, highlighting its relevance for assessing prognosis and measuring treatment efficacy. There were some preliminary indications that MRD status may have a greater effect on outcomes in certain patient subgroups than in others. These data should be interpret- ed with caution, since no significant differential subgroup
effects were seen, and most of the confidence intervals overlapped.
Our data build upon evidence from a recent meta-analy- sis of patients with B-ALL or T-ALL by Berry et al. that showed hazard ratios for event-free survival and OS almost uniformly favor MRD negativity, and that this
Figure 3. Forest plot of relapse-free survival hazard ratios by subgroup (random effects model). B cell ALL/B-ALL: B-cell acute lymphoblastic leukemia; CI: confi- dence interval; CR1: first complete remission; CR2: second complete remission; Chemo: chemotherapy; Flow: flow cytometry; HR: hazard ratio; HSCT: hematopoietic stem-cell transplantation; MRD: minimal residual disease; MRD neg: minimal residual disease-negative status; MRD pos: minimal residual disease-positive status; N: number of studies; PCR: polymerase chain reaction; Ph: Philadelphia chromosome; SCT: stem-cell transplantation; targeted: targeted agent (e.g., tyrosine kinase inhibitor, blinatumomab, inotuzumab); tx: treatment.
2034
haematologica | 2019; 104(10)